Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types

Area of Science:

• Epigenetics and Cancer Biology
• Genomics and Transcriptomics
• Drug Discovery

Background:

• Polycomb repressive complex 2 (PRC2) is crucial for transcriptional repression and implicated in carcinogenesis.
• Core PRC2 components (EZH2, SUZ12, EED) methylate histone H3K27, a key epigenetic mark.
• Small molecule inhibitors targeting PRC2 are under development for cancer therapy.

Purpose of the Study:

• To identify cancer types where PRC2-targeting drugs may be beneficial.
• To evaluate clinical correlations of PRC2 subunit gene alterations (amplification, mutation, expression) with patient prognosis.
• To identify potential biomarkers for sensitivity to PRC2 inhibition.

Main Methods:

• Analysis of genomic and transcriptomic data from clinical tumor samples using cBioPortal and KMplot.
• Evaluation of gene amplification, mutation, and expression of PRC2 subunits (EZH2, SUZ12, EED).
• Development of a Python application to correlate CRISPR-based gene knockouts with cancer cell line data (DepMap) for sensitivity analysis.

Main Results:

• EZH2, SUZ12, and EED gene amplification frequently observed in prostate cancer; EZH2 mutations common in lymphoid malignancies (DLBCL).
• PRC2 alterations consistently associated with poor prognosis across multiple cancer types.
• Higher PRC2 subunit expression correlated with poorer survival in renal, liver cancers, and gliomas.
• SWI/SNF, COMPASS/COMPASS-like subunits, and BCL2 mutations identified as potential markers for PRC2 knockout sensitivity.

Conclusions:

• PRC2 alterations are significant indicators of poor prognosis in various cancers.
• Genomic and transcriptomic profiling of PRC2 subunits can identify susceptible cancer types for targeted therapies.
• Specific gene mutations (SWI/SNF, COMPASS, BCL2) may predict sensitivity to PRC2-targeting drugs, guiding personalized treatment strategies.